Governments have integrated incentives to accelerate and promote the approval of orphan drugs and the interest among pharmaceutical companies to develop these products is rising. However, expedited regulatory approval is by no means an assurance that orphan drugs will succeed in the marketplace.
Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]
In an effort to contain costs and avoid the over-valuing of products, payer organisations in the pharmaceutical and life science industries have made price setting a standard practice. One solution that potentially prevents over-valuation of medicines is External Reference Pricing (ERP). However, with greater amounts of data due to research and technological developments, increased adoption […]